Research

List of articles in category Research
Title
Get Involved
International Research
New Irish Study Shows carriers of the Z Alpha-1 Gene who smoke are at Increased Risk of COPD
Research Breakthrough in Understanding Alpha-1 by Irish Scientists
International Collaborative Study To Establish The 1st International (WHO) Standard for Alpha-1 Antitrypsin
High Prevalence of Alpha-1 Antitrypsin Deficiency in Ireland
American Thoracic Society Annual Conference 2008
Award to Study Immune Cell Function in Alpha-1 Antitrypsin Deficiency
Elucidation of Unfolded Protein Response pathways activated in Lung and Liver Disease associated with Z Alpha-1 Antitrypsin Deficiency
Identification and characterisation of novel pro-inflammatory proteases that excerbate lung disease associated with Z alpha-1 antitrypsin deficiency
Clarification of the Risk of COPD in Alpha-1 antitrypsin (MZ) Individuals
Alpha-1 Augmentation Therapy Clinical Trial
Pilot Alpha-1 Antitrypsin Deficiency Screening Programme to determine the Prevalence of Alpha-1 Antitrypsin Deficiency in Ireland
National Alpha-1 Antitrypsin Deficiency Targeted Detection Programme

Info Centre

What is Alpha-1 Antitrypsin?

Alpha-1 antitrypsin is a vital protein produced by the liver to protect the lungs. It provides protection from the harmful effects of infections and inhaled irritants, particularly tobacco smoke. It can be easily measured by a simple blood test.

What is Alpha-1 Antitrypsin Deficiency?

Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, after cystic fibrosis, is the commonest genetic disorder in Ireland. It severely affects more than 15,000 people, with another 250,000 carriers also at risk of lung and liver disease on the island of Ireland. It is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD).

How Do I Get Tested?

The Alpha One Foundation provides free testing for Alpha-1 as part of a national screening programme which is funded by the HSE. For more details ring 01-8093871 or email This email address is being protected from spambots. You need JavaScript enabled to view it..